. 2019 Jul 15;8(8):1159–1167. doi: 10.1530/EC-19-0243
This work is licensed under a Table 2.
Clinical and biochemical characteristics of the PCOS phenotypes.
| Control group (n = 51) | Phenotype A (n = 18) | Phenotype B (n = 16) | Phenotype C (n = 13) | Phenotype D (n = 10) | |
|---|---|---|---|---|---|
| Age (years) | 26.3 ± 4.3 | 25.5 ± 4.6 | 26.5 ± 5.2 | 24.4 ± 3.9 | 26.5 ± 5.4 |
| BMI (kg/m2) | 22.8 ± 3.1 | 22.8 ± 4.9 | 24.4 ± 3.3 | 23.8 ± 3.6 | 23.2 ± 3.1 |
| Waist circumference (cm) | 79.5 ± 8.3 | 84.1 ± 12.3 | 84.2 ± 9.6 | 80.4 ± 9.4 | 80.9 ± 8.5 |
| Hip circumference (cm) | 98.7 ± 7.1 | 99.3 ± 9.3 | 102.1 ± 4.0 | 98.7 ± 9.9 | 98.6 ± 7.6 |
| Fat free mass (kg) | 44.8 ± 3.7 | 44.5 ± 4.4 | 47.0 ± 8.6 | 44.8 ± 3.4 | 43.6 ± 3.9 |
| Fat mass (%) | 28.9 ± 6.3 | 32.9 ± 4.4 | 32.5 ± 9.4 | 29.9 ± 7.9 | 32.2 ± 7.5 |
| Follicle-stimulating hormone (IU/L) | 5.4 ± 1.7 | 6.3 ± 3.6 | 4.9 ± 1.7 | 4.4 ± 1.6 | 4.8 ± 1.3 |
| Luteinizing hormone (IU/L) | 4.1 ± 1.2 | 5.1 ± 1.5a | 5.2 ± 2.2 | 5.8 ± 0.8 | 5.5 ± 1.3 |
| Total testosterone (ng/mL) | 0.56 ± 0.1 | 0.8 ± 0.2a | 0.6 ± 0.2 | 0.7 ± 0.1a | 0.5 ± 0.1 |
| SHBG (nmol/L) | 66.0 ± 30.2 | 42.2 ± 28.3a | 43.2 ± 33.5a | 56.2 ± 0.3a | 85.9 ± 66.6 |
| FAI | 3.4 ± 2.5 | 8.7 ± 5.0a | 6.3 ± 3.5a | 7.0 ± 6.3a | 2.7 ± 1.8 |
| PRL (ng/mL) | 15.5 ± 14.0 | 14.2 ± 11.9 | 12.0 ± 6.3 | 22.2 ± 19.1 | 14.9 ± 10.0 |
| Glucose 0′ OGTT (mg/dL) | 94.1 ± 9.5 | 93.5 ± 5.7 | 92.8 ± 7.4 | 90.2 ± 8.9 | 91.6 ± 6.3 |
| Glucose 60′ OGTT (mg/dL) | 97.7 ± 20.5 | 136 ± 39.1a | 116 ± 37.9 | 99.4 ± 24.2 | 108 ± 35.8 |
| Glucose 120′ OGTT (mg/dL) | 88.8 ± 16.6 | 102 ± 26.2a | 94.4 ± 19.5 | 93.7 ± 20.1 | 92.1 ± 22.6 |
| Insulin 0′ OGTT (µIU/mL) | 10.0 ± 4.8 | 10.2 ± 3.9 | 9.9 ± 4.1 | 10.2 ± 5.0 | 8.6 ± 3.2 |
| Insulin 60′ OGTT (µIU/mL) | 55.9 ± 45.8 | 84.6 ± 50.9 | 69.2 ± 42.3 | 64.8 ± 57.6 | 65.2 ± 23.5 |
| Insulin 120′ OGTT (µIU/mL) | 30. ± 18.3 | 74.4 ± 90.5a | 29.6 ± 13.5 | 41.6 ± 34.5 | 37.1 ± 20.1 |
| HOMA-IR | 2.2 ± 1.1 | 2.4 ± 0.9 | 2.3 ± 1.0 | 2.3 ± 1.3 | 1.9 ± 0.8 |
| HOMA-B | 125 ± 70 | 123 ± 43 | 123 ± 56 | 140 ± 66 | 113 ± 56 |
| Total cholesterol (mg/dL) | 175 ± 28 | 174 ± 23 | 162 ± 18 | 163 ± 24 | 175 ± 31 |
| HDL cholesterol (mg/dL) | 65.7 ± 20.7 | 61.9 ± 21.2 | 59.4 ± 13.4 | 69 ± 10.2 | 71.2 ± 17.1 |
| LDL cholesterol (mg/dL) | 91.5 ± 24.3 | 95.9 ± 18.4 | 89.2 ± 23.3 | 82.2 ± 19.1 | 91.5 ± 26.1 |
| TG (mg/dL) | 62.0 ± 28.0 | 83.5 ± 62.4a | 69.6 ± 39.7 | 60.1 ± 14.2 | 63.4 ± 21.0 |
| Fetuin-B (µg/mL) | 79.2 ± 16.7 | 88.1 ± 26.4 | 79.6 ± 14.8 | 98.9 ± 25.4a | 82.5 ± 33.4 |
| VAI | 0.78 ± 0.48 | 1.5 ± 1.7a | 1.1 ± 0.9 | 0.7 ± 0.2 | 0.7 ± 0.3 |
| LAP | 15.7 ± 10.7 | 28.7 ± 37.1a | 22.8 ± 21.7 | 15.3 ± 7.4 | 17.3 ± 9.6 |
| FLI | 8.0 ± 10.2 | 20.0 ± 25.2a | 16.4 ± 23.9 | 11.3 ± 16.4 | 9.9 ± 10.1 |
| GGT | 9.4 ± 2.7 | 12.4 ± 5.5a | 14.0 ± 10.5a | 13.4 ± 8.9a | 12.9 ± 8.8a |
Data are presented as mean ± s.d. The level of significance was accepted at aP < 0.05 PCOS vs control group.
BMI, body mass index; FAI, free androgen index; FLI, fatty liver index; GGT, gamma-glutamyl transferase; HOMA-B; homeostatic model assessment β cell function; HOMA-IR, homeostasis model assessment of insulin resistance; LAP, lipid accumulation product; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; SHBG, serum sex hormone–binding globulin; TG, triglycerides; VAI, visceral adiposity index.